Malaysian Cobra Venom: A Potential Source of Anti-Cancer Therapeutic Agents

Syafiq Asnawi Zainal Abidin 1,2, Yee Qian Lee 2, Iekhsan Othman 1,2 and Rakesh Naidu 2,*

1 Liquid Chromatography Mass Spectrometry (LCMS) Platform, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia; syafiq.asnawi@monash.edu (S.A.Z.A.);
iekhsan.othman@monash.edu (I.O.)
2 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia; Yee.Lee@monash.edu
* Correspondence: rakesh.naidu@monash.edu

Received: 17 December 2018; Accepted: 24 January 2019; Published: 1 February 2019

Abstract: Cancer is a deadly disease and there is an urgent need for the development of effective and safe therapeutic agents to treat it. Snake venom is a complex mixture of bioactive proteins that represents an attractive source of novel and naturally-derived anticancer agents. Malaysia is one of the world’s most biodiverse countries and is home to various venomous snake species, including cobras. Naja kaouthia, Naja sumatrana, and Ophiophagus hannah are three of the most common cobra species in Malaysia and are of medical importance. Over the past decades, snake venom has been identified as a potential source of therapeutic agents, including anti-cancer agents. This present review highlights the potential anticancer activity of the venom and purified venom protein of N. kaouthia, N. sumatrana, and O. hannah. In conclusion, this review highlights the important role of the venom from Malaysian cobras as an important resource that researchers can exploit to further investigate its potential in cancer treatment.

Keywords: snake venom; Malaysian cobras; N. kaouthia; N. sumatrana; O. hannah; anticancer

Key Contribution: In this review, the anticancer activity of the venom and purified venom proteins of Malaysian common cobra species are discussed.

1. Introduction

Cancer is a major health problem that affects people all over the world. Globally, 25% of human mortality is due to cancer. In the United States, cancer was reported as the second leading cause of death in 2015. Approximately 1,735,350 new cancer cases and 609,640 deaths due to cancer were expected in 2018 [1]. In Malaysia, cancer remains one of the leading causes of death, and a total of 64,725 deaths were reported from 2007 to 2011 [2]. Cancer is a group of diseases that arises from the uncontrollable proliferation of malignant cells. It is a multigenic and multistage disease due to multifactorial etiology [3]. Briefly, high levels of exposure to carcinogens such as radiation, tobacco, and oncogenic viruses increase the risk of DNA damage in the cells. The DNA-repair mechanism will be initiated at this stage. However, when the damage is too extensive, the repair of lesions fails. This gives rise to changes in the expression of genes (such as tumor-suppressor genes) in the cells, which further alter the signalling pathways resulting in unrestricted cell growth [4].

Even though the incidence of cancer is increasing globally, the mortality rate of cancer is reported to be in decline for the past 20 years [5]. This may be due to the advancement of therapeutic regimes over the past few decades. Various therapeutic options such as surgery, chemotherapy, radiotherapy, and immunotherapy are employed in treating localized cancer. Surgery in combination
with chemotherapy is still the main treatment option. Unfortunately, owing to its cytotoxic activity via the inhibition of nucleic acid synthesis, chemotherapy often results in the death of fast growing cells such as white blood cells, hair follicles, and cells lining the gastrointestinal tract in addition to cancer cells [6]. Therefore, patients often suffer from side effects such as nausea and hair loss. A weakened immune system due to the reduction of white blood cell levels during chemotherapy increases patients’ susceptibility to infection. The development of drug resistance during chemotherapy further complicates the treatment of cancer. Hence, there is an urgent need for effective cancer therapeutics with lesser side effects.

Malaysia, as the 12th most biodiverse country in the world, is the home to approximately 170,000 species of flora and fauna. Since ancient times, natural resources have been exploited to treat diseases and improve human health. For instance, the use of Orthosiphon aristatus (Misai Kuching) as a natural remedy against diabetes is common among indigenous communities in Malaysia [7,8]. Poisonous animals also play a vital role in the discovery of novel therapeutic candidates. For example, bee venom therapy is used to relieve pain symptoms and treat diseases such as rheumatoid arthritis [9,10] and other neurological diseases [11,12]. Venom from the Indian black scorpion was found to induce DNA fragmentation and reduce the proliferation of human leukemic cells [13]. Additionally, a novel peptide named Gonearrestide from scorpion venom showed the inhibition of primary colon cancer cells and solid tumor growth [14]. Commercialized drugs such as Captopril® and Enalpril® are two successful antihypertensive drugs developed based on bradykinin peptides derived from the venom of the snake Bothrops jararaca [15,16]. Ziconotide is another FDA-approved analgesic medication derived from ω-conotoxin that was found in the venom of Conus magnus, a marine snail [17]. By reviewing the pharmaceutical potential of animal venoms, we conclude that the complex mixture of proteins may have the potential to be an important source of therapeutic agents.

Snake venom has been associated with various therapeutic applications—as a thrombolytic agent in cardiovascular disorders [18], anti-microbial activities [19], as an anti-viral agent [20] and in antiparasitic, and antifungal activities [21,22]. Undeniably, the anticancer activities of snake venom represent one of its most attractive therapeutic features and they have been actively researched and reviewed over the past decade [23–25]. The venom from Malaysian common cobras has been characterized, and proteins with anticancer potential have been described. However, while there are numerous reviews focusing on the anticancer activities of snake venom in general, none have focused on the Malaysian common cobra species, i.e., Naja kaouthia, Naja sumatrana, and Ophiophagus hannah.

The abundance of these cobra species provides valuable access for researchers to further investigate the venom activity. Therefore, the present review highlights the anticancer activity of the venom components of Malaysian cobra species.

2. Malaysian Common Cobras

Malaysian venomous snake species can be divided into two families, Viperidae and Elapidae [26,27]. Viperidae can be further divided into three families, Azemiopinae (Fea’s viper), Crotalinae (pit vipers), and Viperinae (true vipers). Malaysian vipers belong to the subfamily Crotalinae, which can be distinguished by the loreal pit on either side of the eyes [26]. Additional characteristics of pit vipers include hollow and retractile fangs on a moveable maxillary bone; a stocky, keel-scaled body with elliptical pupils; and that they are ovoviparous [26]. Elapidae is represented by cobras, kraits, and coral snakes that produce neurotoxic venom. It is characterized as a family of snakes with short and sharp fangs located anteriorly on the maxillary bone, with smooth-scaled body with rounded pupils, and that are oviparous [26]. Three cobra species, namely Naja kaouthia, Naja sumatrana and Ophiophagus hannah are the most common cobras in Malaysia. N. kaouthia or monocled cobra was formerly known as Naja naja siamensis, a subspecies of the Indian cobra (Naja naja) [26]. N. sumatrana is a spitting cobra and it is the most common Elapid of the ten species in the family. Both N. kaouthia and N. sumatrana can inhabit a wide range of environments, ranging from natural to anthropogenic
landscapes. Members of the *Naja* genus are well known to be aggressive and envenomation is common for both species as humans infringe on their niche during the progress of urbanization. The third Malaysian cobra species is *O. hannah* or king cobra. *Ophiophagus*, meaning snake eater in Greek, is a monotypic genus, where the king cobra is the only species in this genus. It is the longest venomous snake species and is a dreadful assailant that is famous for its agility. The fatality rate incurred by king cobra envenomation is relatively high, although bites are rarely reported [26]. Table 1 provides a summary of comparisons between the cobras. In spite of their toxicity, the venom of Malaysian cobras demonstrates a wide range of therapeutic potential through antibacterial [28,29], anticancer [30–33], anticonvulsant [34], and antithrombotic [35] activities.

### Table 1. Comparison of the cobra species in Malaysia.

| Characteristics | *Naja kaouthia* | *Naja sumatrana* | *Ophiophagus hannah* |
|-----------------|-----------------|------------------|---------------------|
| Length          | Usually 4–5 feet, occasionally can reach up to 7.5 feet | Usually 3–3.9 feet, occasionally can reach up to 4.9 feet | Usually 8–18 feet |
| Distribution in Malaysia | Peninsular Malaysia, mainly in the northern part of peninsular Malaysia | Peninsular Malaysia, Sabah, and Sarawak | Peninsular Malaysia, Sabah, and Sarawak |
| Habitat         | Not habitat-specific, can adapt to a wide range of habitats such as grassland and paddy fields | Not habitat-specific, can adapt to a wide range of habitats such as primary and secondary forests and human-surrounding environments | Habitat-specific, mainly inhabits forests |
| Proteomic composition of the venom | 3FTx, PLA₂, ohanin, CRVP, SVMP, vNGF, cardiotxin, CVF, cytotoxin, and neurotoxin [36,37] | PLA₂, neurotoxins, cardiotxin, cytotoxin, 3FTX, CVF, SVMP, CRVP, natriuretic peptide, aminopeptidase, thiacobilin, complement-depleting factor, vNGF, and cobra serum albumin [38] | Natriuretic peptides, 3FTx, Kunitz-type inhibitor, PLA₂, ohanin, CRVP, cystatin, insulin-like growth factor, SVMP, LAAO, SVSP, vNGF, vPDE, PLB, AChE, 5’NUC, and neprilysins [31,39] |

Abbreviations: 3FTx—three-finger toxin, PLA₂—phospholipase A₂, CRVP—cysteine-rich venom protein, SVMP—snake venom metalloprotease, vNGF—venom nerve-growth factor, CVF—cobra venom factor, LAAO—L-amino acid oxidase, vPDE—venom phosphodiesterase, SVSP—snake venom serine protease, PLB—phospholipase B, AChE—acetylcholinesterase, 5’NUC—5’-nucleotidase.

### 3. Proteomic Composition of the Venom from *N. kaouthia*, *N. sumatrana*, and *O. hannah*

Snake venom is a natural resource that can be readily obtained, especially from Malaysian *N. kaouthia*, *N. sumatrana*, and *O. hannah*. The evolutionary arms race has driven the diversification of toxins in snake venom. It is a complex mixture comprising: 1) proteins such as phospholipase A₂ (PLA₂), L-amino acid oxidase (LAAO), acetylcholinesterase, and protease; 2) peptides such as disintegrins; 3) low-molecular-weight organic compounds such as carbohydrates and histamines; and 4) inorganic ions such as magnesium, cobalt, iron, and potassium [40]. The cocktail of proteins in snake venom aids the snakes in capturing and digesting their prey. These proteins can be categorized as cytotoxins, hemotoxins, neurotoxins, and cardiotoxins [4]. However, the composition of snake venoms may have inter- and intraspecies variation, depending on habitat, diet, gender, and ontogenetic development [4,41].
The advancement of mass spectrometry techniques has allowed for the proteomic characterization of the venom from *N. kauithia*, *N. sumatrana*, and *O. hannah*. A combination of transcriptomic and proteomic analyses of *N. kauithia* venom has identified proteins such as the three-finger toxin (3FTx), phospholipase A2 (PLA2), ohanin, cysteine-rich venom protein (CRVP), snake venom metalloproteinase (SVMP), venom nerve-growth factor (vNGF), cobra venom factor (CVF), cardiotoxin, cytotoxin, and neurotoxin [36,37]. The proteomic characterization of *N. sumatrana* venom identified proteins including PLA2, neurotoxins, cardiotoxin, cytotoxin, 3FTx, CVF, SVMP, CRVP, natriuretic peptide, aminopeptidase, thiacobrin, complement-depleting factor, kaouthin-1, vNGF, and cobra serum albumin [38]. Similar proteins, such as 3FTx, SVMP, PLA2, and LAAO, were also identified from the venom of *O. hannah* in addition to acetylcholinesterase (AChE), phospholipase B (PLB), 5'-nucleotidase (5'NUC), neprilysins, and cystatins [31,39].

The common and unique venom proteins from *N. kauithia*, *N. sumatrana*, and *O. hannah* are summarized in Figure 1. Five proteins were found to be common to all three cobra species, namely, 3FTx, PLA2, CRVP, SVMP, and vNGF. Between *N. kauithia* and *N. sumatrana*, four shared proteins were identified, including cardiotoxin, cytotoxin, neurotoxin, and CVF. Ohanin was found in both *N. kauithia* and *O. hannah* and natriuretic peptides were identified in both *N. sumatrana* and *O. hannah*. Cobra serum albumin, aminopeptidase, thiacobrin, and complement-depleting factor were unique in *N. sumatrana* venom. Nine proteins in *O. hannah* venom were identified to be unique when compared with *N. kauithia* and *N. sumatrana*, such as, LAAO, Kunitz-type inhibitor, cystatin, insulin-like growth factor, venom phosphodiesterase (vPDE), 5'NUC, snake venom serine protease (SVSP), AChE, and neprilysins.

**Figure 1.** Common and unique proteins identified from the venom of *Naja kauithia*, *Naja sumatrana*, and *Ophiophagus hannah*. Abbreviations: 3FTx—three-finger toxin, PLA2—phospholipase A2, CRVP—cysteine-rich venom protein, SVMP—snake venom metalloproteinase, vNGF—venom nerve-growth factor, CVF—cobra venom factor, LAAO—L-amino acid oxidase, vPDE—venom phosphodiesterase, SVSP—snake venom serine protease, AChE—acetylcholinesterase, 5'NUC—5'-nucleotidase.

4. Potential AntiCancer Activity of Malaysian Cobra Venom

The idea of utilizing snake venom as an important source of therapeutic agents and focusing on its anticancer properties has been extensively reviewed [23,24,42]. The investigation of snake venom’s effects on cancers can be traced back as early as the 1930s [43,44]. Since then, various snake venom proteins—most notably, LAAO, PLA2, SVMP/disintegrins, and snake venom C-type lectins
(SNACLEC)—have been isolated and characterized for their activity as potential anticancer agents. The large amount of venom that can be obtained from the Malaysian common cobras renders them valuable for further investigation into potential therapeutic uses, especially as anticancer agents. The anticancer activity of the venom from the cobras is summarized in Table 2.

Table 2. Anticancer activity of Malaysian common cobra crude venom and protein components.

| Species          | Venom/Protein Component | Mechanism                                                                 | Cancer Cell Type/Tissue | Reference |
|------------------|-------------------------|---------------------------------------------------------------------------|-------------------------|-----------|
| **Ophiophagus hannah** | Crude venom             | Cytotoxic activity on pancreatic cancer cells (EC$_{50}$; 1.39 ng/mL), reduced migration activity, and induction of apoptosis in PaTu 8988t cells | PaTu 8988t              | [45]      |
|                  | Crude venom             | Reduced tumor-cell-induced angiogenesis in vivo                           | Zebrafish embryos      | [45]      |
|                  | L-amino acid oxidase (OH-LAAO) | Antiproliferative activity on murine melanoma, human fibrosarcoma, and murine epithelial cells | B16/F10, HT1080, and Balb/3T3 | [30]      |
|                  | OH-LAAO                 | Cytotoxic activity on human breast adenocarcinoma cells (EC$_{50}$ 0.05 µg/mL) and apoptosis induction | MCF-7                  | [33]      |
|                  | OH-LAAO                 | Apoptosis induction and inhibition of prostate tumor growth                | PC-3 xenograft in nude mice | [32]      |
|                  | OH-LAAO                 | Induced alteration of gene expression involved in cytotoxicity and apoptotic effects Modulation of proteins involved in stress response, ubiquitination, proteolyis, cell proliferation, and apoptosis | MCF-7                  | [31]      |
|                  | OH-LAAO                 | Cytotoxic activity on pancreatic cancer cells (EC$_{50}$ 1.42 ng/mL)       | PaTu 8988t              | [45]      |
|                  | Crude venom             | Venom at a nonlethal dose inhibited tumor-cell proliferation and showed cytotoxic activity and apoptosis induction in human lung cancer cells and leukemic cells | Ehrlich-ascites cells (EAC), U937, K562 | [47]      |
|                  | Cytotoxin CT3           | Histopathological changes in leukemia cells treated with CT3               | A549 and HL60           | [48]      |
|                  | Cardiotoxic-cytotoxic protein | Antiproliferative activity and apoptosis induction in human leukemic cells | U947 and K562           | [49]      |
|                  | kaotree (N. kouthia) and atroporin (Crotalus atrox) combination | Elevated cytotoxic activity in various human cancer cells                  | HBL-100, BT-20, ZR-75-1, HT-29, and Diji | [50]      |

4.1. Ophiophagus Hannah

In a recent study by Kerkkamp et.al [45], the cytotoxic activity of crude O. hannah and N. kaouthia venom was demonstrated on the human pancreatic cancer cell line (PaTu 8988t) at an EC$_{50}$ value of 1.39 ng/mL and 1.42 ng/mL, respectively. Selective cytotoxic activity was demonstrated by the crude venoms with EC$_{50}$ values of approximately 20 ng/mL on the control cell lines (ZF4 cells; zebrafish cells) [45]. Furthermore, in-vitro migration and apoptosis assays demonstrated the ability of crude
O. hannah venom to reduce cell migration activity and induce apoptosis, respectively [45]. Using an in-vivo zebrafish model, PaTu 8988t cells were injected post fertilization of the zebrafish to induce an angiogenic response. Treatment with O. hannah venom successfully inhibited the angiogenesis induction of the cancer cells [45].

LAAO is one of the major enzymatic protein components in O. hannah venom. The enzyme is categorized under flavoenzymes, which convert L-amino acid into alpha-keto acids with hydrogen peroxide (H$_2$O$_2$) as a byproduct [40]. The cytotoxic activity of LAO from different snake species, including pit vipers and cobras, has been demonstrated in various human cancer cells [51–53]. The production of H$_2$O$_2$ was noted to be the main cause of cytotoxicity in several experiments [30,54–56]. The apoptosis-inducing activities of snake venom LAAO were also associated with the secondary production of H$_2$O$_2$ [57,58], but the specific mechanism remains unknown [40]. Interestingly, a study has demonstrated that LAAO was able to trigger the apoptotic mechanism even without the presence of H$_2$O$_2$ [59]. In 2014, Lee et al. [46] demonstrated the antiproliferative activity of OH-LAAO purified from O. hannah (OH-LAAO) on human breast adenocarcinoma (MCF-7) and human lung adenocarcinoma (A549) with EC$_{50}$ values of 0.04 µg/mL and 0.05 µg/mL, respectively. The cytotoxic activity was demonstrated to be selective on the cancer cells with greater potency when compared with doxorubicin, an established chemotherapeutic agent [33]. The induction of apoptosis partly contributed to the cytotoxic mechanism, as demonstrated by the increased level of caspase-3/7 and DNA fragmentation [33]. Similarly, OH-LAAO demonstrated cytotoxic activity against human prostate adenocarcinoma (PC-3) with an EC$_{50}$ value of 0.05 µg/mL [32]. The in-vivo activity of OH-LAAO on nude mice implanted with PC-3 cells showed a significant reduction of tumor size with no obvious tissue damage in their vital organs [32]. These findings support an earlier study of OH-LAAO cytotoxicity on several cancer cell lines by Ahn et al. [30]. The investigators demonstrated the antiproliferative activity of OH-LAAO in murine melanoma cells (B16/F10) and human fibrosarcoma cells (HT1080) with approximately 74% inhibition at a concentration of 2 µg/mL.

Fung and co-investigators [31] identified a total of 178 genes with significant alteration in MCF-7 cells treated with OH-LAAO. Amongst these were genes associated with the induction of apoptosis, such as, BMF (Bcl2 modifying factor), IGFBP3 (insulin-like growth-factor-binding protein 3), PLEKHF1 (Pleckstrin homology domain-containing, family F member 1), and PPARG (peroxisome proliferator-activated receptor gamma) [31]. Recent proteomic investigations by Fung et al. [46] further suggest that the use of OH-LAAO on MCF-7 induced 21 differentially expressed proteins with various biological functions including apoptosis, proteolysis, stress response, protein ubiquitination, and oxidoreduction. The authors concluded that the nonspecific oxidative modification of transcriptional factors caused by OH-LAAO is the key factor in the cell death and apoptosis induction.

4.2. Naja Kaouthia

Feofanov et al. [48] demonstrated that cytotoxin (CT3) from N. kaouthia induced strong cytotoxic activity in human lung adenocarcinoma (A549) and human promyelotic leukemia cells (HL60) at an EC$_{50}$ value of 2.6 µM and 0.18 µM, respectively. The authors further suggest that the cytotoxic effects of CT3 in HL60 were noted by their ability to bind strongly to the plasma membrane followed by internalization of the protein [48]. Furthermore, lysosomes were identified as the primary target of the cytotoxin that triggered the cytolytic action on the cells. [48]. Permeabilization of the plasma membrane was noted as a downstream event following lysosome rupture [48]. Interestingly, cytotoxins from other cobra species such as Naja oxiana and Naja haje demonstrated weak internalization of the protein in the plasma membrane compared to CT3. In a separate study investigating the anticancer activity of N. kaouthia crude venom by Debnath et al. [47], nonlethal doses of the crude venom inhibited the proliferation of various cancer cell lines such as Ehrlich-ascites cells (EAC), human lung lymphoblasts (U937), and human myelogenous leukemia cells (K562). Morphological changes associated with apoptosis such as membrane blebbing, chromatin condensation, and fragmentation were common
features in cells treated with the *N. kaouthia* venom [47]. Furthermore, the solid-tumor growth of sarcomas using a Balb/c mice model was significantly reduced when treated with *N. kaouthia* crude venom [47].

In a follow-up study by Debnath et al. [49] on *N. kaouthia*, a lethal protein named cardiotoxic–cytotoxic protein was purified from the crude venom. The protein was identified through sequence homology to cytotoxins and cardiotoxins from the venom of other cobra species and demonstrated significant antiproliferative activity on human leukemic cells (U937 and K562) in a dose-dependent manner [49]. The leukemic cells treated with the cardiotoxic–cytotoxic protein demonstrated an increase of caspase-3/-9 activity and an increase of the proapoptotic Bax level, which suggest the induction of apoptosis [49]. Additionally, a novel protein, named Kaotree, has been identified and characterized from the venom of *N. kaouthia* with reports of selective cytotoxic activity on transformed mammary epithelial cells (HBL-100), mammary gland carcinoma (BT-20), breast cancer cells (ZR-75-1), and colon adenocarcinoma (HT-29) [50]. The anticancer activity of Kaotree was demonstrated to have an enhanced killing effect when combined with Atroporin, a snake venom protein derived from *Crotalus atrox* [50]. A patent was filed for the anticancer activity of Kaotree and Atroporin (US Patent No: 5565431) with the claim of a novel method for treating cancer patients.

4.3. *Naja Sumatrana*

While the anticancer activity of the crude venom of *O. hannah* and *N. kaouthia* has been well documented, to date, there is no available literature on *N. sumatrana* venom. However, proteomic characterization of *N. sumatrana* venom has identified major proteins with well-reported anticancer activity, such as PLA2, cardiotoxin, and neurotoxin [38]. The anticancer potential of snake venom PLA2 has been well reviewed [60] and the protein has been isolated from various snake species such as vipers [61,62], sea snakes [63], and cobras [64]. The cytotoxicity and anticancer activity of PLA2 has been demonstrated by MjTX-II, a PLA2 isolated from *Bothrops moojeni*, on treated EAC cancer cells, human breast carcinoma (SK-BR-3), and human T-cell leukemia (Jurkat) [65]. Ammodytoxin C, PLA2 purified from *Vipera ammodytes*, showed antitumoral activity against colon adenocarcinoma (Caco-2) [66]; and RVV-7, a cytotoxic PLA2 from *Daboia russellii*, displayed significant inhibition in B16F10 tumors in C57BL/6 mice [67]. In addition to its cytotoxic activity, snake venom PLA2 could also be employed as a model for drug development in humans. A study by Sales et al. [68] demonstrated similar interactions between PLA2 from *Bothrops* species and human-secreted PLA2 (HGIIA); which catalyzes the production of potent inflammatory molecules and is commonly associated with diseases [69]. Therefore, the anti-inflammatory activity of a novel drug can be studied using snake venom PLA2 for therapy models in humans. Cardiototoxin (CTX-III) isolated from *Naja atra* venom has demonstrated anticancer activities in oral squamous cell carcinoma (Ca9-22) [70], human breast cancer cells (MDA-MB-231) [71], and human neuroblastoma cells (SK-N-SH) [72]. Cell death by CTX-III in all cell lines was attributed to the induction of apoptosis through a significant increase of caspase-3/-9 activity and cell cycle arrest. Alpha-cobrotoxin (α-CbT), a neurotoxin purified from *N. kaouthia* venom, prolonged the survival of animals in a non-small cell lung cancer (NSCLC) mouse model [73].

5. Future Directions and Conclusions

Cancer remains one of the most critical health burden worldwide, including in Malaysia. The disease presents a major challenge in the discovery and production of therapeutic agents that are effective, nontoxic, and cause fewer side effects. Anticancer agents from naturally derived sources—especially animal venom—have demonstrated their potential in cancer therapy. Venom-based protein/peptide therapeutics has been a subject of interest over the past few decades. Venomous animals such as scorpions and snakes were widely studied for their therapeutic values with some advantages and some challenges coming to light [24,74,75]. One of the major promises of a venom-based therapeutic agent is the specificity and the selectivity of its interaction with the
target molecule. This is crucial to developing an anticancer agent with the ability to differentiate between normal and cancerous cells, with significant impact on cell proliferation, migration, and angiogenesis [76]. Moreover, some venom peptides, such as cytotoxins from *N. kaouthia* [47] are small and are able to penetrate cancer cells to trigger the cytotoxic effect. However, because of its toxic nature and our incomplete understanding of the anticancer mechanism of the venom proteins/peptides, the number of venom-based therapeutic agents currently in the market are very low [77].

Technological advancement in proteomics and genomics approaches, such as mass spectrometry and sequencing techniques, have allowed multiple proteins from venom to be isolated and characterized for activity. Proteins such as LAAO, PLA$_2$, cytotoxin, and SVMP can be purified, characterized, and further investigated to determine the mechanisms by which they induce anticancer activity in vitro and in vivo. The majority of the studies mentioned in this review focused on the cytotoxicity of the venom/purified venom proteins on cancer cells, but further studies are needed to elucidate the potential anticancer mechanisms. Data obtained from the studies can serve as a template for further preclinical and clinical studies to demonstrate the safety and efficacy of these anticancer proteins. The delivery of the venom protein/peptide-based therapeutics represents another challenge in this field. However, continued advancements in the field of molecular biology, recombinant proteins, and drug delivery, such as nanoparticles, could possibly overcome the issues of bioavailability, pharmacokinetics, and efficacy of snake venom proteins as an anticancer drug. A study by Al-Sadoon et al. [77] demonstrated that the venom from *Walterinnesia aegyptia* combined with silica nanoparticles strongly induced apoptosis in human breast cancer cells with no significant impact on normal breast epithelial cells. In another study, the combination of venom and silica nanoparticles showed greater suppression of tumor growth in an in vivo model in nude mice compared to the venom alone [78].

In conclusion, this present review demonstrates that the venom from Malaysian common cobras could exert anticancer effects by modulating the cancer cell development mechanism and triggering apoptosis. The widespread availability of the cobras *N. kaouthia*, *N. sumatrana*, and *O. hannah* in the wild in Malaysia provides a valuable opportunity for researchers to further investigate their venom as a source of potential anticancer agents.

Author Contributions: S.A.Z.A and Y.Q.L. wrote the manuscript. I.O. and R.N. edited and reviewed the manuscript.

**Funding:** This research received no external funding.

**Acknowledgments:** We would like to thank Mr. Zainuddin Ismail (Bukit Bintang Enterprise, Perlis) for his expertise and advice in snake handling. Y.Q.L. is supported by Monash University Malaysia through a merit scholarship for their master’s study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. *CA Cancer J. Clin.* 2018, 68, 7–30. [CrossRef] [PubMed]

2. Omar, Z.A.; Ibrahim Tamin, N. *National Cancer Registry Report: Malaysia Cancer Statistics-Data and Figure; National Cancer Registry: Putrajaya, Malaysia, 2011*; pp. 85–87.

3. Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.-W. Cancer and radiation therapy: Current advances and future directions. *Int. J. Med. Sci.* 2012, 9, 193. [CrossRef] [PubMed]

4. Jain, D.; Kumar, S. Snake venom: A potent anticancer agent. *Asian Pac. J. Cancer Prev.* 2012, 13, 4855–4860. [CrossRef] [PubMed]

5. Wang, L.; Dong, C.; Li, X.; Han, W.; Su, X. Anticancer potential of bioactive peptides from animal sources (review). *Oncol. Rep.* 2017, 38, 637–651. [CrossRef] [PubMed]

6. Libero, M.S.; Joanitti, G.A.; Fontes, W.; Castro, M.S. Anticancer peptides and proteins: A panoramic view. *Protein Pept. Lett.* 2013, 20, 380–391. [PubMed]
7. Mustaffa, F.; Indurkar, J.; Ali, N.; Hanapi, A.; Shah, M.; Ismail, S.; Mansor, S. A review of Malaysian medicinal plants with potential antidiabetic activity. *J. Pharm. Res.* 2011, 4, 4217–4224. [CrossRef] [PubMed]
8. Tan, K.Y.; Tan, C.H.; Fung, S.Y.; Tan, N.H. Venomics, lethality and neutralization of *Naja kaouthia* (monocled cobra) venoms from three different geographical regions of Southeast Asia. *J. Proteome* 2015, 120, 105–125. [CrossRef] [PubMed]
9. Hong, S.-J.; Rim, G.S.; Yang, H.I.; Yin, C.S.; Koh, H.G.; Jang, M.-H.; Kim, C.-J.; Choe, B.-K.; Chung, J.-H. Bee venom induces apoptosis through caspase-3 activation in synovial fibroblasts of patients with rheumatoid arthritis. *Toxicon* 2005, 46, 39–45. [CrossRef] [PubMed]
10. Lee, J.-D.; Kim, S.-Y.; Kim, T.-W.; Lee, S.-H.; Yang, H.-I.; Lee, D.-I.; Lee, Y.-H. Anti-inflammatory effect of bee venom on type II collagen-induced arthritis. *Am. J. Chin. Med.* 2004, 32, 361–367. [CrossRef] [PubMed]
11. Cho, S.-Y.; Shim, S.-R.; Rhee, H.Y.; Park, H.-J.; Jung, W.-S.; Moon, S.-K.; Park, J.-M.; Ko, C.-N.; Cho, K.-H.; Park, S.-U. Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson’s Disease. *Parkinsonism Relat. Disord.* 2012, 18, 948–952. [CrossRef] [PubMed]
12. Kim, J.-I.; Yang, E.J.; Lee, M.S.; Kim, Y.-S.; Huh, Y.; Cho, I.-H.; Kang, S.; Koh, H.-K. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson’s Disease. *Int. J. Neurosci.* 2011, 121, 209–217. [CrossRef] [PubMed]
13. Gupta, S.D.; Deb Nath, A.; Saha, A.; Giri, B.; Tripathi, G.; Vedasiromoni, J.R.; Gomes, A.; Gomes, A. Indian black scorpion (*Heterometrus bengalensis* Koch.) venom induced antiproliferative and apoptogenic activity against human leukemic cell lines U937 and K562. *Leuk. Res. Rev.* 2007, 31, 817–825. [CrossRef] [PubMed]
14. Li, B.; Lyu, P.; Xi, X.; Ge, L.; Mahadevappa, R.; Shaw, C.; Kwok, H.F. Triggering of cancer cell cycle arrest by a novel venom-derivated peptide—Gonearestide. *J. Cell Mol. Med.* 2018, 22, 4460–4473. [CrossRef] [PubMed]
15. Cushman, D.W.; Ondetti, M.A. History of the design of captopril and related inhibitors of angiotensin converting enzyme. *Hypertension* 1991, 17, 589–592. [CrossRef] [PubMed]
16. Ferreira, S. A bradykinin-potentiating factor (BPF) present in the venom of *Bothrops jararaca* (black scorpion, *Heterometrus*). *Br. J. Pharmacol.* 1965, 24, 163–169. [CrossRef]
17. Pope, J.E.; Deer, T.R. Ziconotide: A clinical update and pharmacologic review. *Expert Opin. Pharmacother.* 2013, 14, 957–966. [CrossRef] [PubMed]
18. Koh, C.Y.; Kini, R.M. From snake venom toxins to therapeutics—Cardiovascular examples. *Toxicon* 2012, 59, 497–506. [CrossRef] [PubMed]
19. Wen, Y.L.; Wu, B.J.; Kao, P.H.; Fu, Y.S.; Chang, L.S. Antibacterial and membrane-damaging activities of β-bungarotoxin b chain. *J. Pept. Sci.* 2013, 19, 1–8. [CrossRef]
20. Muller, V.D.; Russo, R.R.; Cintra, A.C.; Sartim, M.A.; Alves-Paiãa, M.; Figueiredo, L.T.; Sampaio, S.V.; Aquino, V.H. Crototoxin and phospholipases A2 from *Crotalus durissus terrificus* showed antiviral activity against dengue and yellow fever viruses. *Toxicon* 2012, 59, 507–515. [CrossRef]
21. Castillo, J.C.Q.; Vargas, L.J.; Segura, C.; Gutiérrez, J.M.; Pérez, J.C.A. In vitro antiplasmodial activity of phospholipases A2 and a phospholipase homologue isolated from the venom of the snake *Bothrops asper*. *Toxins* 2012, 4, 1500–1516. [CrossRef]
22. Yamane, E.S.; Bizzera, F.C.; Oliveira, E.B.; Moreira, J.T.; Rajabi, M.; Nunes, G.L.; de Souza, A.O.; da Silva, I.D.; Yamane, T.; Karpel, R.L. Unraveling the antifungal activity of a South American rattlesnake toxin crotamine. *Biochimie* 2013, 95, 231–240. [CrossRef] [PubMed]
23. Calderon, L.A.; Sobrinho, J.C.; Zaqueo, K.D.; de Moura, A.A.; Grabner, A.N.; Mazzi, M.V.; Marcussi, S.; Nomizo, A.; Fernandes, C.F.; Zuliani, J.P.; et al. Antitumor activity of snake venom proteins: New trends in cancer therapy. *BioMed Res. Int.* 2014, 2014, 203639. [CrossRef] [PubMed]
24. Li, L.; Huang, J.; Lin, Y. Snake venom in cancer therapy: Past, present and future. *Toxins* 2018, 10, 346. [CrossRef] [PubMed]
25. Vyas, V.K.; Brahmbhatt, K.; Bhatt, H.; Parmar, U. Therapeutic potential of snake venom in cancer therapy: Current perspectives. *Asian Pac. J. Trop. Biomed.* 2013, 3, 156–162. [CrossRef]
26. Das, I.; Ahmed, N.; Liat, L.B. Venomous terrestrial snakes of Malaysia: Their identity and biology. *Clin. Toxicol.* 2013, 1–15. [CrossRef]
27. Tweedie, M.W.F. *The Snakes of Malaya*, 3rd ed.; Singapore National Printers: Singapore, 1983; 167p.
28. Lee, M.L.; Tan, N.H.; Fung, S.Y.; Sekaran, S.D. Antibacterial action of a heat-stable form of L-amino acid oxidase isolated from king cobra (Ophiophagus hannah) venom. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* 2011, 153, 237–242. [CrossRef] [PubMed]

29. Phua, C.; Vejayan, J.; Ambu, S.; Ponnudurai, G.; Gorajana, A. Purification and antibacterial activities of an L-amino acid oxidase from king cobra (Ophiophagus hannah) venom. *J. Venom. Anim. Toxins Incl. Trop. Dis.* 2012, 18, 198–207. [CrossRef]

30. Ahn, M.Y.; Lee, B.M.; Kim, Y.S. Characterization and cytotoxicity of L-amino acid oxidase from the venom of king cobra (Ophiophagus hannah). *Int. J. Biochem. Cell Biol.* 1997, 29, 911–919. [CrossRef]

31. Fung, S.Y.; Lee, M.L.; Tan, N.H. Molecular mechanism of cell death induced by king cobra (Ophiophagus hannah) venom L-amino acid oxidase. *Toxicon* 2015, 96, 38–45. [CrossRef] [PubMed]

32. Lee, M.L.; Fung, S.Y.; Chung, I.; Pailoor, J.; Cheah, S.H.; Tan, N.H. Antibacterial action of L-amino acid oxidase induces apoptosis in PC-3 cells and suppresses PC-3 solid tumor growth in a tumor xenograft mouse model. *Int. J. Med. Sci.* 2014, 11, 593. [CrossRef] [PubMed]

33. Li Lee, M.; Chung, I.; Yee Fung, S.; Kanthimathi, M.S.; Hong Tan, N. Antiproliferative activity of king cobra (Ophiophagus hannah) venom L-amino acid oxidase. *Basic Clin. Pharmacol. Toxicol.* 2014, 114, 336–343. [CrossRef] [PubMed]

34. Saha, A.; Gomes, A.; Chakravarty, A.; Biswas, A.; Giri, B.; Dasgupta, S. CNS and anticonvulsant activity of a non-protein toxin (KC-MMTX) isolated from king cobra (Ophiophagus hannah) venom. *Toxicon* 2006, 47, 296–303. [CrossRef] [PubMed]

35. Du, X.-Y.; Clemetson, J.M.; Navdaev, A.; Magnenat, E.M.; Wells, T.N.; Clemetson, K.J. Ophioluxin, a convulxin-like C-type lectin from Ophiophagus hannah (king cobra) is a powerful platelet activator via glycoprotein VI. *J. Biol. Chem.* 2002, 277, 35124–35132. [CrossRef] [PubMed]

36. Xu, N.; Zhao, H.Y.; Yin, Y.; Shen, S.S.; Shan, L.L.; Chen, C.X.; Zhang, Y.X.; Gao, J.F.; Ji, X. Combined venomics, antivenomics and venom gland transcriptome analysis of the monocled cobra (*Naja kaouthia*) from China. *J. Proteom.* 2017, 159, 19–31. [CrossRef] [PubMed]

37. Kulkeaw, K.; Chaicumpa, W.; Sakolvaree, Y.; Tongtawe, P.; Tapchaisri, P. Applications of snake venoms in treatment of cancer. *Asian Pac. J. Trop. Biomed.* 2015, 5, 275–276. [CrossRef]

38. Essex, H.E.; Priestley, J.T. Effect of rattlesnake venom on Flexner-Jobling’s carcinoma in the white rat (*Mus norvegicus* Albinus). *Proc. Soc. Exp. Biol. Med.* 1931, 28, 550–551. [CrossRef]

39. Kurotchkin, T.; Spies, J. Effects of cobra venom on the Fujinami rat sarcoma. *Proc. Soc. Exp. Biol. Med.* 1935, 32, 1408–1410. [CrossRef]

40. Kerkkamp, H.; Bagowski, C.; Kool, J.; van Soolingen, B.; Vonk, F.J.; Vlecken, D. Whole snake venoms: Cytotoxic, anti-metastatic and antiangiogenic properties. *Toxicon* 2018, 150, 39–49. [CrossRef] [PubMed]

41. Ahn, M.Y.; Lee, B.M.; Kim, Y.S. Characterization and cytotoxicity of L-amino acid oxidase from the venom of king cobra (Ophiophagus hannah) venom L-amino acid oxidase. *Toxicon* 2011, 53, 198–207. [CrossRef] [PubMed]

42. Shanbhag, V.K.L. Applications of snake venoms in treatment of cancer. *Asian Pac. J. Trop. Biomed.* 2015, 5, 275–276. [CrossRef]

43. Debnath, A.; Chatterjee, U.; Das, M.; Vedasiromoni, J.R.; Gomes, A. Venom of Indian monocellate cobra and Russell’s viper show anticancer activity in experimental models. *J. Ethnopharmacol.* 2007, 111, 681–684. [CrossRef] [PubMed]
48. Feofanov, A.V.; Sharonov, G.V.; Astapova, M.V.; Rodionov, D.I.; Utkin, Y.N.; Arseniev, A.S. Cancer cell injury by cytotoxins from cobra venom is mediated through lysosomal damage. Biochem. J. 2005, 390, 11–18. [CrossRef] [PubMed]

49. Debath, A.; Saha, A.; Gomes, A.; Biswas, S.; Chakrabarti, P.; Giri, B.; Biswas, A.K.; Gupta, S.D.; Gomes, A. A lethal cardiotoxic-cytotoxic protein from the Indian monocellate cobra (Naja kaouthia) venom. Toxicon 2010, 56, 569–579. [CrossRef] [PubMed]

50. Lipps, B.V. Novel snake venom proteins cytolytic to cancer cells in vitro and in vivo systems. J. Venom. Anim. Toxins Incl. Trop. Dis. 1999, 5, 172–183. [CrossRef]

51. Zainal Abidin, S.A.; Rajadurai, P.; Hoque Chowdhury, M.E.; Othman, I.; Naidu, R. Cytotoxic, Anti-Proliferative and Apoptosis Activity of L-Amino Acid Oxidase from Malaysian Cryptelytrops purpureomaculatus (CP-LAAO) Venom on Human Colon Cancer Cells. Molecules 2018, 23, 1388. [CrossRef] [PubMed]

52. Zainal Abidin, S.A.; Rajadurai, P.; Chowdhury, M.E.H.; Ahmad Rusmili, M.R.; Othman, I.; Naidu, R. Cytotoxic, Antiproliferative and Apoptosis-inducing Activity of L-Amino Acid Oxidase from Malaysian Calloselasma rhodostoma on Human Colon Cancer Cells. Basic Clin. Pharmacol. Toxicol. 2018, 123, 577–588. [CrossRef] [PubMed]

53. Mauro, V.P.; Adriana, S.P.; Andreimar, M.S.; Juliana, P.Z. An Update on Potential Molecular Mechanisms Underlying the Actions of Snake Venom L-amino Acid Oxidases (LAAOs). Curr. Med. Chem. 2018, 25, 2520–2530.

54. Zhang, L.; Wei, L.J. ACTX-8, a cytotoxic L-amino acid oxidase isolated from Agkistrodon acutus snake venom, induces apoptosis in Hela cervical cancer cells. Life Sci. 2007, 80, 1189–1197. [CrossRef] [PubMed]

55. Zhang, L.; Wu, W.T. Isolation and characterization of ACTX-6: A cytotoxic L-amino acid oxidase from Agkistrodon acutus snake venom. Nat. Prod. Res. 2008, 22, 554–563. [CrossRef] [PubMed]

56. Zhang, Y.J.; Wang, J.H.; Lee, W.H.; Wang, Q.; Liu, H.; Zheng, Y.T.; Zhang, Y. Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity. Biochem. Biophys. Res. Commun. 2003, 309, 598–604. [CrossRef] [PubMed]

57. Guo, C.; Liu, S.; Dong, P.; Zhao, D.; Wang, C.; Tao, Z.; Sun, M.Z. Akbu-LAAO exhibits potent anti-tumor activity to HepG2 cells partially through produced H2O2 via TGF-beta signal pathway. Sci. Rep. 2015, 5, 18215. [CrossRef] [PubMed]

58. Ribeiro, P.H.; Zuliani, J.P.; Fernandes, C.F.; Calderon, L.A.; Stabeli, R.G.; Nomizo, A.; Soares, A.M. Mechanism of the cytotoxic effect of L-amino acid oxidase isolated from Bothrops alternatus snake venom. Int. J. Biol. Macromol. 2016, 92, 329–337. [CrossRef] [PubMed]

59. Suhr, S.M.; Kim, D.S. Identification of the snake venom substance that induces apoptosis. Biochem. Biophys. Res. Commun. 1996, 224, 134–139. [CrossRef]

60. Rodrigues, R.S.; Izidoro, L.F.; de Oliveira, R.J., Jr.; Sampaio, S.V.; Soares, A.M.; Rodrigues, V.M. Snake venom phospholipases A2: A new class of antitumor agents. Protein Pept. Lett. 2009, 16, 894–898. [CrossRef]

61. Zouari-Kessentini, R.; Luis, J.; Karray, A.; Kalleh-Ziri, O.; Srairi-Abid, N.; Bazaa, A.; Loret, E.; Bezzine, S.; El Ayeb, M.; Marrakchi, N. Two purified and characterized phospholipases A2 from Cerastes cerastes venom, that inhibit cancerous cell adhesion and migration. Toxicon 2009, 53, 444–453. [CrossRef]

62. Khunsap, S.; Pakmanee, N.; Khow, O.; Chanhome, L.; Sitprija, V.; Suntravat, M.; Lucena, S.E.; Perez, J.C.; Sanchez, E.E. Purification of a phospholipase A2 from Daboia russellii siamensis venom with anticancer effects. J. Venom. Res. 2011, 2, 42–51.

63. Liang, Y.J.; Yang, X.P.; Wei, J.W.; Fu, L.W.; Jiang, X.Y.; Chen, S.W.; Yang, W.L. correlation of antitumor effect of recombinant sea snake basic phospholipase A2 to its enzymatic activity. Ai Zheng 2005, 24, 1474–1478. [PubMed]

64. Chwetzoff, S.; Tsunawasa, S.; Sakiyama, F.; Menez, A. Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties. J. Biol. Chem. 1989, 264, 13289–13297. [PubMed]

65. Rudrammaji, L.M.; Gowda, T.V. Purification and characterization of three acidic, cytotoxic phospholipases A2 from Indian cobra (Naja naja naja) venom. Toxicon 1998, 36, 921–932. [CrossRef]

66. Premzl, A.; Kovacic, L.; Halassy, B.; Krizaj, I. Generation of ammodytoxin-anti-cathepsin B immuno-conjugate as a model for delivery of secretory phospholipase A2 into cancer cells. Toxicon 2008, 51, 754–764. [CrossRef] [PubMed]
67. Maity, G.; Mandal, S.; Chatterjee, A.; Bhattacharyya, D. Purification and characterization of a low molecular weight multifunctional cytotoxic phospholipase A$_2$ from Russell’s viper venom. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2007, 845, 232–243. [CrossRef] [PubMed]

68. Sales, T.A.; Marcussi, S.; Da Cunha, E.F.F.; Kuca, K.; Ramalho, T.C. Can inhibitors of snake venom phospholipases A$_2$ lead to new insights into anti-inflammatory therapy in humans? A theoretical study. *Toxins* 2017, 9, 341. [CrossRef] [PubMed]

69. Quach, N.D.; Arnold, R.D.; Cummings, B.S. Secretory phospholipase A$_2$ enzymes as pharmacological targets for treatment of disease. *Biochem. Pharmacol.* 2014, 90, 338–348. [CrossRef] [PubMed]

70. Chien, C.M.; Chang, S.Y.; Lin, K.L.; Chiu, C.C.; Chang, L.S.; Lin, S.R. Taiwan cobra cardiotoxin III inhibits SRC kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma CA9-22 cells. *Toxicon* 2010, 56, 508–520. [CrossRef] [PubMed]

71. Lin, K.L.; Su, J.C.; Chien, C.M.; Chuang, P.W.; Chang, L.S.; Lin, S.R. Down-regulation of the JAK2/PI3k-mediated signaling activation is involved in taiwan cobra cardiotoxin III-induced apoptosis of human breast MDA-MB-231 cancer cells. *Toxicon* 2010, 55, 1263–1273. [CrossRef]

72. Chen, K.C.; Lin, S.R.; Chang, L.S. Involvement of mitochondrial alteration and reactive oxygen species generation in Taiwan cobra cardiotoxin-induced apoptotic death of human neuroblastoma SK-N-SH cells. *Toxicon* 2008, 52, 361–368. [CrossRef]

73. Paleari, L.; Negri, E.; Catassi, A.; Cilli, M.; Servent, D.; D’Angelillo, R.; Cesario, A.; Russo, P.; Fini, M. Inhibition of non-neuronal α7-nicotinic receptor for lung cancer treatment. *Am. J. Respir. Crit. Care Med.* 2009, 179, 1141–1150. [CrossRef] [PubMed]

74. Ortiz, E.; Gurrola, G.B.; Schwartz, E.F.; Possani, L.D. Scorpion venom components as potential candidates for drug development. *Toxicon* 2015, 93, 125–135. [CrossRef] [PubMed]

75. Ma, R.; Mahadevappa, R.; Kwok, H.F. Venom-based peptide therapy: Insights into anti-cancer mechanism. *Oncotarget* 2017, 8, 100908–100930. [CrossRef] [PubMed]

76. Mahadevappa, R.; Ma, R.; Kwok, H.F. Venom peptides: Improving specificity in cancer therapy. *Trends Cancer* 2017, 3, 611–614. [CrossRef] [PubMed]

77. Al-Sadoon, M.K.; Abdel-Maksoud, M.A.; Rabah, D.M.; Badr, G. Induction of apoptosis and growth arrest in human breast carcinoma cells by a snake (*Walterinnesia aegyptia*) venom combined with silica nanoparticles: Crosstalk between Bcl2 and caspase 3. *Cell Physiol. Biochem.* 2012, 30, 653–665. [CrossRef] [PubMed]

78. Al-Sadoon, M.K.; Rabah, D.M.; Badr, G. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: Molecular targets for cell cycle arrest and apoptosis induction. *Cell. Immunol.* 2013, 284, 129–138. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).